Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Search Results

Product Details for NDA 208510

Expand all

VYVANSE (LISDEXAMFETAMINE DIMESYLATE)
10MG
Marketing Status: Prescription

Active Ingredient: LISDEXAMFETAMINE DIMESYLATE
Proprietary Name: VYVANSE
Dosage Form; Route of Administration: TABLET, CHEWABLE; ORAL
Strength: 10MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N208510
Product Number: 001
Approval Date: Jan 28, 2017
Applicant Holder Full Name: TAKEDA PHARMACEUTICALS USA INC
Marketing Status:  Prescription
Patent and Exclusivity Information

VYVANSE (LISDEXAMFETAMINE DIMESYLATE)
20MG
Marketing Status: Prescription

Active Ingredient: LISDEXAMFETAMINE DIMESYLATE
Proprietary Name: VYVANSE
Dosage Form; Route of Administration: TABLET, CHEWABLE; ORAL
Strength: 20MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N208510
Product Number: 002
Approval Date: Jan 28, 2017
Applicant Holder Full Name: TAKEDA PHARMACEUTICALS USA INC
Marketing Status:  Prescription
Patent and Exclusivity Information

VYVANSE (LISDEXAMFETAMINE DIMESYLATE)
30MG
Marketing Status: Prescription

Active Ingredient: LISDEXAMFETAMINE DIMESYLATE
Proprietary Name: VYVANSE
Dosage Form; Route of Administration: TABLET, CHEWABLE; ORAL
Strength: 30MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N208510
Product Number: 003
Approval Date: Jan 28, 2017
Applicant Holder Full Name: TAKEDA PHARMACEUTICALS USA INC
Marketing Status:  Prescription
Patent and Exclusivity Information

VYVANSE (LISDEXAMFETAMINE DIMESYLATE)
40MG
Marketing Status: Prescription

Active Ingredient: LISDEXAMFETAMINE DIMESYLATE
Proprietary Name: VYVANSE
Dosage Form; Route of Administration: TABLET, CHEWABLE; ORAL
Strength: 40MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N208510
Product Number: 004
Approval Date: Jan 28, 2017
Applicant Holder Full Name: TAKEDA PHARMACEUTICALS USA INC
Marketing Status:  Prescription
Patent and Exclusivity Information

VYVANSE (LISDEXAMFETAMINE DIMESYLATE)
50MG
Marketing Status: Prescription

Active Ingredient: LISDEXAMFETAMINE DIMESYLATE
Proprietary Name: VYVANSE
Dosage Form; Route of Administration: TABLET, CHEWABLE; ORAL
Strength: 50MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N208510
Product Number: 005
Approval Date: Jan 28, 2017
Applicant Holder Full Name: TAKEDA PHARMACEUTICALS USA INC
Marketing Status:  Prescription
Patent and Exclusivity Information

VYVANSE (LISDEXAMFETAMINE DIMESYLATE)
60MG
Marketing Status: Prescription

Active Ingredient: LISDEXAMFETAMINE DIMESYLATE
Proprietary Name: VYVANSE
Dosage Form; Route of Administration: TABLET, CHEWABLE; ORAL
Strength: 60MG
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: AB
Application Number: N208510
Product Number: 006
Approval Date: Jan 28, 2017
Applicant Holder Full Name: TAKEDA PHARMACEUTICALS USA INC
Marketing Status:  Prescription
Patent and Exclusivity Information